PMID- 8225697
OWN - NLM
STAT- MEDLINE
DCOM- 19931215
LR  - 20141120
IS  - 0251-1649 (Print)
IS  - 0251-1649 (Linking)
VI  - 13
IP  - 3
DP  - 1993
TI  - A non-invasive evaluation of flosequinan on haemodynamics and exercise capacity 
      in chronic congestive heart failure.
PG  - 143-9
AB  - The efficacy of flosequinan 100 mg once daily was evaluated in 15 patients with 
      severe congestive heart failure (New York Heart Association [NYHA] class II-IV) 
      who had not responded adequately to digoxin and diuretics. Efficacy assessments 
      using non-invasive techniques included exercise capacity, haemodynamics and left 
      ventricular function. Determinations were made after 3 and 21 days' treatment, 
      and compared with baseline. Flosequinan significantly increased exercise capacity 
      by 27% after 3 days (+79 seconds, p = 0.015) and by 43% after 21 days (+123 
      seconds, p = 0.0007) and was accompanied by an increase in heart rate (+7.2 
      beats/min, p = 0.03; +9.1 beats/min, p = 0.03, respectively). Cardiac index and 
      cardiac output were also significantly increased but only after 21 days' 
      treatment (+0.3 l/min/m2, +16% and +0.5 l/min, +14%, respectively; both p = 
      0.008). Flosequinan was well tolerated, with headache being the most frequently 
      reported adverse event and only 1 patient being withdrawn. One patient died but 
      this was not unexpected in a group of patients with severe heart failure. Using 
      non-invasive techniques this study demonstrated that in patients with severe 
      chronic congestive heart failure, flosequinan increased exercise capacity and 
      cardiac output, the latter being achieved mainly by an increase in heart rate.
FAU - Motro, M
AU  - Motro M
AD  - Heart Institute, Chaim Sheba Medical Center, Tel Hashomer, Israel.
FAU - Freimark, D
AU  - Freimark D
FAU - Feinberg, M S
AU  - Feinberg MS
FAU - Wynne, R D
AU  - Wynne RD
FAU - King, C
AU  - King C
FAU - Schneeweiss, A
AU  - Schneeweiss A
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Int J Clin Pharmacol Res
JT  - International journal of clinical pharmacology research
JID - 8110183
RN  - 0 (Quinolines)
RN  - 0 (Vasodilator Agents)
RN  - 0J48LPH2TH (Hydrochlorothiazide)
RN  - 6NB119DLU7 (flosequinan)
RN  - 7DZO8EB0Z3 (Amiloride)
SB  - IM
MH  - Aged
MH  - Amiloride/therapeutic use
MH  - Cardiac Output/drug effects
MH  - Chronic Disease
MH  - Echocardiography
MH  - Exercise/*physiology
MH  - Exercise Test
MH  - Female
MH  - Heart Failure/*drug therapy/*physiopathology
MH  - Hemodynamics/*drug effects
MH  - Humans
MH  - Hydrochlorothiazide/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Quinolines/adverse effects/*therapeutic use
MH  - Vasodilator Agents/adverse effects/*therapeutic use
MH  - Ventricular Function, Left/drug effects
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
PST - ppublish
SO  - Int J Clin Pharmacol Res. 1993;13(3):143-9.